Pembrolizumab 联合紫杉醇用于铂耐药复发性卵巢癌的经济性分析
Pembrolizumab plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer with PD-L1 CPS ≥ 1: a cost-effectiveness analysis
研究采用 Markov 模型评估 Pembrolizumab 联合紫杉醇(可选贝伐珠单抗)治疗 PD-L1 CPS ≥ 1 的铂耐药复发性卵巢癌患者的经济性。在美国,该方案每 QALY 成本为 752,613 美元,高于 WTP 门槛;在中国,每 QALY 成本为 61,777 美元。价格降低后,该方案在中国更具经济吸引力。
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Patients with platinum-resistant recurrent ovarian cancer (PRROC) have limited therapeutic options. Pembrolizumab plus paclitaxel with optional bevacizumab (pembrolizumab group) has recently emerged as a promising therapeutic strategy for this population. Nevertheless, the high acquisition and treatment costs associated with this regimen raise important concerns regarding its economic value, making a formal cost-effectiveness evaluation essential. A three-state Markov model with a 15-year time horizon was constructed using clinical efficacy data from the KEYNOTE-B96 trial together with treatment-related cost inputs for estimating lifetime costs and health outcomes for PRROC patients with PD-L1 combined positive score (CPS) ≥ 1 receiving either the pembrolizumab regimen or placebo. Outcomes included total costs, quality-adjusted life-years (QALYs), incremental net health benefits (INHBs), and incremental cost-effectiveness ratios (ICERs). Cost-effectiveness was assessed using willingness-to-pay (WTP) thresholds of $150,000/QALY for the USA and $40,500/QALY for China. In the USA, treatment with pembrolizumab resulted in an additional cost of $214,982 and a gain of 0.29 QALYs compared with placebo. In China, the corresponding incremental cost and QALY gain were $16,459 and 0.27, respectively. The resulting ICERs were $752,613/QALY in the USA and $61,777/QALY in China, with associated INHBs of -1.14 QALYs and -0.14 QALYs, respectively. Sensitivity analyses showed that when pembrolizumab prices were reduced by 10% in the USA and 30% in China, the ICERs declined to levels below the respective WTP thresholds. At current market prices, pembrolizumab plus paclitaxel with optional bevacizumab does not represent a cost-effective option for PRROC. However, price reductions for pembrolizumab could substantially improve its economic attractiveness.
Acknowledgements
N/A.
Funding
N/A.
Author information
Authors and Affiliations
Department of Gastrointestinal Surgery, Jinjiang Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Quanzhou, 362201, Fujian, China
Yixin Lin
Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, EnshClinical College of Wuhan University, Enshi, 445000, Hubei, China
Kun Chen & Dong Ding
Authors
- Yixin Lin
- Kun Chen
- Dong Ding
Corresponding authors
Correspondence to Kun Chen or Dong Ding.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
This article is based on the data from the previously conducted and publicly published KEYNOTE-B96 trial (PMID: 41974150), which does not include individual patient data. The authors have not conducted any new research involving humans or animals, and therefore do not need to obtain approval from an independent ethics committee.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Lin, Y., Chen, K. & Ding, D. Pembrolizumab plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer with PD-L1 CPS ≥ 1: a cost-effectiveness analysis. Sci Rep (2026). https://doi.org/10.1038/s41598-026-77527-0
Received: 24 July 2026
Accepted: 20 October 2026
Published: 31 October 2026
DOI: https://doi.org/10.1038/s41598-026-77527-0
Keywords
来源:Nature 健康护理主题 · nature.com